Reviewing past treatment and survival in people with high-grade osteosarcoma
Looks back at records of people treated for high-grade osteosarcoma in Korea.
Key facts
- Who runs it
- MedPacto, Inc.
- Where
- Goyang-si and Seoul, South KoreaSee the 4 sites
- Trial code
- Registry title
- Treatment Patterns and Survival Outcomes in High-Grade Osteosarcoma: A Multicenter Retrospective Study
- Status
- Recruiting
- People taking part
- 400 people, planned
- Started
- 13 Jul 2026
- Expected to end
- 31 Dec 2027
- Type of study
- Observational
- Record updated
- 16 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
This record-review study looks at people aged 12 or older with high-grade osteosarcoma (a bone cancer). Their first treatment had to be completed or ended at a study hospital on or before 2021-06-30.
- Age
- 12 years or older
- Sex
- All sexes can join
- Disease stage
- High-grade osteosarcoma confirmed by pathology (tissue examination)
- Earlier treatment
- First-line treatment for high-grade osteosarcoma completed or ended at the study hospital on or before 2021-06-30
Main reasons for not taking part
- Primary tumor that began in soft tissue rather than bone
- Another cancer in the past, unless clinically insignificant and fully treated before the osteosarcoma
- Key data for the survival analysis cannot be verified
- Moved to another hospital with no follow-up information available
- Data errors or inconsistencies judged by the investigator
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Pathologically diagnosed high-grade osteosarcoma; age ≥12 years
- First-line treatment for high-grade osteosarcoma completed or ended at the study institution on or before 2021-06-30
- Core data required for survival endpoint assessment (EFS, PFS, OS) are available, with at least one of the following satisfied: (a) at least 12 months of follow-up from the date of diagnosis; or (b) an event (relapse, metastasis, disease progression, or death from any cause) confirmed within 12 months of diagnosis
Who cannot take part
- History of a malignancy other than primary osteosarcoma, unless clinically insignificant and fully treated prior to osteosarcoma diagnosis with no investigator-judged impact on osteosarcoma treatment course or survival analysis
- Primary tumor of soft-tissue origin rather than bone, confirmed pathologically
- Core data required for survival analysis cannot be verified
- Transferred to another institution with no available follow-up information, where neither event occurrence, last follow-up date, nor survival status can be determined from pre-transfer records
- Investigator-judged data errors or inconsistencies
Where in South Korea
- National Cancer CenterGoyang-si, South KoreaContact: Prof. June-Hyuk KimTaking people
- Asan Medical CenterSeoul, South KoreaContact: Prof. Kyung-Nam KohNot yet recruiting
- Korea Cancer Center HospitalSeoul, South KoreaContact: Prof. Wan-Hyeong ChoTaking people
- Seoul National University HospitalSeoul, South KoreaContact: Prof. Hyoung-Jin KangNot yet recruiting
About the trial
What the trial wants to find out
This is a multicenter, medical-record-based, retrospective observational study of approximately 400 patients with high-grade osteosarcoma treated at four sites in the Republic of Korea. The study describes treatment patterns and survival outcomes (event-free survival [EFS], progression-free survival [PFS], and overall survival [OS]) in patients who completed or discontinued first-line treatment for high-grade osteosarcoma, irrespective of complete remission status. The primary objective is to retrospectively estimate the 12-month EFS rate, calculated from the date of diagnosis, in the full cohort of high-grade osteosarcoma patients. Key secondary objectives evaluate EFS and OS from the date of confirmed complete remission/no evidence of disease (CR/NED) in the subset of clinically high-risk patients who achieve CR/NED, in order to establish a historical reference data supporting the design and interpretation of a future prospective clinical trial of vactosertib as maintenance therapy.
The group in the trial
- High-grade Osteosarcoma Cohort
Retrospectively identified patients with high-grade osteosarcoma who meet the study eligibility criteria.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter Medical-Record-Based Retrospective Study of Treatment Patterns and Survival Outcomes in Patients With High-Grade Osteosarcoma
- Plain-language title
- Reviewing past treatment and survival in people with high-grade osteosarcomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 16 October 2026